ISSN: 1465-6566

Journal Home

Journal Guideline

Expert Opinion on Pharmacotherapy Q2 Unclaimed

Taylor and Francis Ltd. United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Expert Opinion on Pharmacotherapy is a journal indexed in SJR in Medicine (miscellaneous) and Pharmacology with an H index of 93. It has a price of 2395 €. It has an SJR impact factor of 0,687 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,687.

Expert Opinion on Pharmacotherapy focuses its scope in these topics and keywords: treatment, management, cancer, therapeutic, inhibitors, pharmacological, update, clinical, colorectal, concerns, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Medicine (miscellaneous) (Q2) Pharmacology (Q2) Pharmacology (medical) (Q2) Pharmacology (medical) (Q2)

Price

2395 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

0,687

SJR Impact factor

93

H Index

206

Total Docs (Last Year)

669

Total Docs (3 years)

15644

Total Refs

1640

Total Cites (3 years)

573

Citable Docs (3 years)

2.15

Cites/Doc (2 years)

75.94

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Clinical Rheumatology Q2
Pharmacological Reports Q2
Journal of Human Nutrition and Dietetics Q2
Diseases of the Colon and Rectum Q2
Oncology Reports Q2

Compare this journals

Aims and Scope

Best articles by citations

Current and emerging pharmacotherapy for the treatment of bacterial peritonitis

Diastolic heart failure: recognition, diagnosis and management

Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma

Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer

The role of growth hormone-receptor antagonism in relation to acromegaly

New phosphodiesterase inhibitors in the treatment of erectile dysfunction

Erratum

Efficacy and safety of ibandronate in the treatment of neoplastic bone disease

Teneligliptin: expectations for its pleiotropic action

Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis

Current and future perspectives on the treatment of cerebral ischemia

Gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer: a prospective observational study

SHOW MORE ARTICLES

Bedaquiline and delamanid in tuberculosis

Erratum

A review of the second-generation antihistamine ebastine for the treatment of allergic disorders

Recent advances, trends and economic considerations in the risk assessment, prevention and treatment of postoperative nausea and vomiting

Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents

Clinical-economic appropriateness of drug treatments: designing a method that combines evidence-based information and cost assessments to construct league tables accounting for the potential number of patients

Brinzolamide

Current and future treatment options for community-associated MRSA infection

Assessing the efficacy of medical treatments for alcohol use disorders

Evaluating the novel application of cyclosporine 0.1% in ocular surface disease

Brinzolamide plus brimonidine for the treatment of glaucoma: an update

Fungicidal versus Fungistatic: what's in a word?